Open AccessIntratumoral immunosuppression profiles in 11q‐deleted neuroblastomas provide new potential therapeutic targets
Author(s) -
Coronado Esther,
Yañez Yania,
Vidal Enrique,
Rubio Luis,
VeraSempere Francisco,
CañadaMartínez Antonio José,
Panadero Joaquín,
Cañete Adela,
Ladenstein Ruth,
Castel Victoria,
Font de Mora Jaime
Publication year - 2021
Publication title -
molecular oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.332
H-Index - 88
eISSN - 1878-0261
pISSN - 1574-7891
DOI - 10.1002/1878-0261.12868
Subject(s) - immunotherapy , immune system , immunosuppression , neuroblastoma , cancer research , biology , oncology , population , immunology , medicine , genetics , cell culture , environmental health
High‐risk 11q‐deleted neuroblastomas display features of a higher immunosuppression microenvironment than other high‐risk neruoblastomas. Efficacy of current anti‐GD2 immunotherapy in 11q‐deleted neuroblastomas may be reduced by inhibition of effector cells by kynurenine production and tryptophan depletion by IDO1, polarized M2 macrophages, PD‐L1 expression, and IL‐10‐dependent Treg conversion from resting CD4+ T cells, providing a rationale for further combination immunotherapy studies.